Ironwood Pharmaceuticals Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Der Umsatz und der Gewinn von Ironwood Pharmaceuticals werden voraussichtlich um 9.8% bzw. 11.5% pro Jahr zurückgehen, während der Gewinn je Aktie voraussichtlich um 24% pro Jahr steigen wird.
Wichtige Informationen
-11.5%
Wachstumsrate der Gewinne
24.03%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 25.2% |
| Wachstumsrate der Einnahmen | -9.8% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 07 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • Jun 22
IRWD: Expanded Constipation Indication And 2026 Outlook Will Support Future Upside
Analysts have modestly revised their price target for Ironwood Pharmaceuticals to $10.00, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E. These revisions leave their fair value estimate unchanged at $10.00.
Narrativ-Update • Jun 08
IRWD: Pediatric Expansion And Stable Guidance Will Support Future Upside Potential
Analysts have adjusted their $ price target on Ironwood Pharmaceuticals, reflecting updated assumptions for discount rate, revenue growth, profit margins, and future P/E, and are now framing the stock's valuation through a more measured growth outlook. What's in the News The U.S. FDA approved LINZESS (linaclotide) for functional constipation in pediatric patients 2 to 5 years old, expanding the prior indication that started at age 6 and keeping LINZESS as the only FDA approved prescription therapy for pediatric functional constipation, according to the company.Narrativ-Update • May 25
IRWD: Maintained 2026 Revenue Outlook Will Support Long Term Cash Flows
Analysts have kept their price target for Ironwood Pharmaceuticals steady at $10.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E that they view as better aligned with the company’s current risk and earnings profile. What's in the News Chief Financial Officer Gregory Martini plans to resign effective May 15, 2026.Seeking Alpha • May 22
Ironwood Pharmaceuticals: A Contrarian Buy Opportunity
Summary Ironwood Pharmaceuticals presents a contrarian buy opportunity after a 14.5% decline driven by CFO resignation and insider selling. At the current $3.49 quote, IRWD fundamentals remain intact, supported by an SA Quant STRONG BUY rating and a base-case target of $6.90, implying ~100% upside. Short-term volatility is attributed to management changes and insider sales, but underlying cash generation and business model remain intact. IRWD's revenue structure, based on profit-sharing with AbbVie for LINZESS, results in lumpy earnings and a compressed multiple. Read the full article on Seeking AlphaAnalyseartikel • May 11
Results: Ironwood Pharmaceuticals, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
A week ago, Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) came out with a strong set of quarterly numbers that could...Narrativ-Update • May 01
IRWD: Earnings Outlook And Trial Updates Will Limit Future Share Upside
Analysts have slightly adjusted their price target on Ironwood Pharmaceuticals, citing updated assumptions for discount rate, revenue growth, profit margins, and future P/E, while keeping their fair value estimate broadly unchanged at $3.70. What's in the News Ironwood plans to present data from the LANDMARK survey at the 2026 Digestive Disease Week meeting in Chicago, highlighting healthcare professional views on the burden of total parenteral nutrition for short bowel syndrome and preferred attributes for new therapies that reduce dependence on parenteral support (company announcement).Narrativ-Update • Apr 17
IRWD: Extended Revenue Guidance And Margin Assumptions Will Restrain Future Upside
Analysts have slightly adjusted their price target on Ironwood Pharmaceuticals, reflecting small tweaks to inputs such as discount rate, revenue growth assumptions, profit margin outlook and the future P/E multiple, while keeping their overall fair value estimate steady at $3.70. What's in the News Ironwood Pharmaceuticals reiterated its earnings guidance for 2026, stating that total revenue is expected to be in the range of $450 million to $475 million.Narrativ-Update • Apr 02
IRWD: Multi Year Revenue Guidance And Margin Assumptions Will Shape Outlook
Analysts have raised their price target on Ironwood Pharmaceuticals by $3, reflecting updated assumptions around fair value, a lower discount rate, higher projected revenue growth, a materially stronger profit margin outlook, and a reduced future P/E multiple. What's in the News Ironwood Pharmaceuticals reiterated earnings guidance for 2026, with total revenue expected in the range of $450 million to $475 million (company guidance).Narrativ-Update • Mar 19
IRWD: Reinforced 2026 Guidance And Legal Resolution Will Support Future Cash Flows
Analysts have modestly adjusted their price target on Ironwood Pharmaceuticals, now reflecting a $10.00 fair value that aligns with updated assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Ironwood Pharmaceuticals reiterated earnings guidance for 2026, with total revenue expected in a range of $450 million to $475 million.Narrativ-Update • Mar 05
IRWD: Index Inclusion And Reinforced Guidance Will Support Future Cash Flows
Analysts have raised their fair value estimate for Ironwood Pharmaceuticals from $8.00 to $10.00, citing updated assumptions for revenue growth, profit margins, and future P/E expectations built into their models. What's in the News Ironwood Pharmaceuticals reiterated its 2026 earnings guidance, with total revenue expected in a range of $450 million to $475 million.Narrativ-Update • Feb 19
IRWD: Medicare Pricing Clarity Will Support Future Cash Flows And Optionality
Analysts have raised their price target on Ironwood Pharmaceuticals to $3.80 from $1.70, citing clearer visibility on future Linzess pricing after the Centers for Medicare and Medicaid Services set a negotiated $136 Medicare price for a 30 day supply. They view this as supportive of the company as it reviews alternatives.
Narrativ-Update • Feb 05
IRWD: Medicare Pricing Clarity And Revenue Outlook Will Shape Balanced Share Prospects
Ironwood Pharmaceuticals' analyst price target has moved higher, with the fair value estimate shifting from about US$2.50 to roughly US$4.85. Analysts cite updated revenue growth, profit margin and future P/E assumptions, along with recent Medicare pricing clarity for Linzess, as key drivers of their revised view.Narrativ-Update • Jan 22
IRWD: Medicare Pricing Clarity Will Support Future Earnings And Deal Optionality
Narrative Update Overview Analysts have raised their price target for Ironwood Pharmaceuticals to US$3.80 from US$1.70, citing clearer visibility on future Linzess Medicare pricing following the recent Inflation Reduction Act negotiation outcomes. Analyst Commentary Bullish analysts are highlighting the recent Medicare pricing outcome for Linzess as an important input into their updated view on Ironwood Pharmaceuticals.Narrativ-Update • Jan 07
IRWD: Medicare Price Certainty Will Support Stronger Earnings And Optionality
Analysts have lifted their 12 month fair value estimate for Ironwood Pharmaceuticals from $3.80 to $8.00, citing clearer Medicare pricing for Linzess and what they view as a stronger setup as the company reviews potential alternatives. Analyst Commentary Recent research has focused on how clearer Medicare pricing for Linzess could affect Ironwood Pharmaceuticals' valuation and options review.Analyseartikel • Jan 06
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Shares Bounce 32% But Its Business Still Trails The Industry
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shares have continued their recent momentum with a 32% gain in the last...Narrativ-Update • Dec 13
IRWD: Medicare Pricing Clarity Will Support More Predictable Earnings And Balanced Outlook
Analysts have lifted their price target on Ironwood Pharmaceuticals to $3.80 from $1.70, citing improved visibility on Linzess Medicare pricing that supports higher long term profitability. This, they say, justifies a lower discount rate, a more stable revenue outlook, and a richer fair value assessment.Narrativ-Update • Nov 28
IRWD: Future Share Price Could Weaken Amid Upcoming Medicare Price Cuts
Analysts have increased their price target for Ironwood Pharmaceuticals to $3.80 from $1.70. They cite greater clarity on future Medicare pricing and strategic opportunities following recent policy announcements.Narrativ-Update • Nov 13
IRWD: Future Expectations May Not Justify Recent Share Price Levels
Analysts have raised their price target for Ironwood Pharmaceuticals from $0.95 to $1.85. They cited improved revenue growth projections, a reduced discount rate, and a substantial increase in expected profit margins.Analyseartikel • Nov 12
Need To Know: Analysts Are Much More Bullish On Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Revenues
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shareholders will have a reason to smile today, with the analysts making...Analyseartikel • Nov 06
There's No Escaping Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Muted Revenues Despite A 39% Share Price Rise
Despite an already strong run, Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shares have been powering on, with a gain...Narrativ-Update • Oct 29
Worsening Revenue Outlook Will Limit Upside Despite Improving Profit Margins
Analysts have lowered their price target for Ironwood Pharmaceuticals from $0.95 to $0.95, citing reduced revenue growth expectations. This has been offset by improved profit margins and a lower discount rate.Analyseartikel • Sep 10
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 33% But Its Business Prospects Need A Lift Too
Despite an already strong run, Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shares have been powering on, with a gain...Analyseartikel • Jun 25
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Held Back By Insufficient Growth Even After Shares Climb 28%
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shareholders are no doubt pleased to see that the share price has...Analyseartikel • Dec 21
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shareholders would be excited to see that the share price has had a...Analyseartikel • Oct 24
Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 1.6x Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) is...
Neues Narrativ • Sep 17
LINZESS And Apraglutide Set To Power Through Market Challenges With Strong Growth Prospects
LINZESS prescription growth indicates strong market acceptance, potentially increasing revenue as it gains market share.Analyseartikel • Aug 16
Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There
The market seemed underwhelmed by the solid earnings posted by Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) recently...Analyseartikel • Jun 27
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough
You may think that with a price-to-sales (or "P/S") ratio of 2.4x Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) is...Seeking Alpha • Jun 20
Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC
Summary Ironwood Pharmaceuticals, Inc. data from the phase 2 proof-of-concept study, using CNP-104 for the treatment of patients with primary biliary cholangitis, expected in Q3 of 2024. The global primary biliary cholangitis therapeutics market size is projected to reach $1.4 billion by 2032. NDA filing and other regulatory filings across the globe of apraglutide for the treatment of patients with short bowel syndrome who are dependent on parenteral support. Ironwood Pharmaceuticals had cash and cash equivalents of $121.5 million as of March 31st of 2024; Enough cash to fund its operations for at least the next 12 months. Read the full article on Seeking AlphaGewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 489 | 232 | 277 | 277 | 3 |
| 12/31/2027 | 478 | 210 | 270 | 270 | 4 |
| 12/31/2026 | 459 | 188 | 238 | 238 | 4 |
| 3/31/2026 | 362 | 102 | 112 | 112 | N/A |
| 12/31/2025 | 296 | 24 | 127 | 127 | N/A |
| 9/30/2025 | 339 | 29 | 68 | 68 | N/A |
| 6/30/2025 | 309 | -8 | 30 | 30 | N/A |
| 3/31/2025 | 318 | -32 | 78 | 79 | N/A |
| 12/31/2024 | 351 | 1 | 103 | 104 | N/A |
| 9/30/2024 | 378 | -2 | 124 | 124 | N/A |
| 6/30/2024 | 401 | 9 | 146 | 147 | N/A |
| 3/31/2024 | 414 | -1,052 | 148 | 148 | N/A |
| 12/31/2023 | 443 | -1,002 | 183 | 183 | N/A |
| 9/30/2023 | 432 | -952 | 227 | 227 | N/A |
| 6/30/2023 | 427 | -917 | 263 | 263 | N/A |
| 3/31/2023 | 417 | 182 | 290 | 290 | N/A |
| 12/31/2022 | 411 | 175 | 274 | 274 | N/A |
| 9/30/2022 | 421 | 168 | 259 | 259 | N/A |
| 6/30/2022 | 416 | 173 | 265 | 265 | N/A |
| 3/31/2022 | 422 | 527 | 252 | 252 | N/A |
| 12/31/2021 | 414 | 528 | 262 | 262 | N/A |
| 9/30/2021 | 413 | 530 | 249 | 249 | N/A |
| 6/30/2021 | 413 | 509 | 227 | 227 | N/A |
| 3/31/2021 | 398 | 143 | 199 | 199 | N/A |
| 12/31/2020 | 390 | 106 | 167 | 169 | N/A |
| 9/30/2020 | 399 | 111 | 140 | 145 | N/A |
| 6/30/2020 | 427 | 97 | 118 | 126 | N/A |
| 3/31/2020 | 440 | 84 | 88 | 97 | N/A |
| 12/31/2019 | 428 | 59 | N/A | 11 | N/A |
| 9/30/2019 | 433 | 19 | N/A | -8 | N/A |
| 6/30/2019 | 367 | -153 | N/A | -69 | N/A |
| 3/31/2019 | 346 | -173 | N/A | -82 | N/A |
| 12/31/2018 | 347 | -194 | N/A | -71 | N/A |
| 9/30/2018 | 310 | -190 | N/A | -89 | N/A |
| 6/30/2018 | 331 | -71 | N/A | -94 | N/A |
| 3/31/2018 | 315 | -108 | N/A | -104 | N/A |
| 12/31/2017 | 298 | -55 | N/A | -101 | N/A |
| 9/30/2017 | 292 | -143 | N/A | -110 | N/A |
| 6/30/2017 | 271 | -143 | N/A | -80 | N/A |
| 3/31/2017 | 260 | -121 | N/A | -53 | N/A |
| 12/31/2016 | 274 | -82 | N/A | -26 | N/A |
| 9/30/2016 | 240 | -82 | N/A | -26 | N/A |
| 6/30/2016 | 213 | -96 | N/A | -52 | N/A |
| 3/31/2016 | 187 | -123 | N/A | -71 | N/A |
| 12/31/2015 | 150 | -143 | N/A | -107 | N/A |
| 9/30/2015 | 134 | -166 | N/A | -110 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: IRWDFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-11.5% pro Jahr).
Ertrag vs. Markt: IRWDFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-11.5% pro Jahr).
Hohe Wachstumserträge: IRWDFür die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.
Einnahmen vs. Markt: IRWDDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-9.8% pro Jahr).
Hohe Wachstumseinnahmen: IRWDDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-9.8% pro Jahr).
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von IRWD in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/01 22:46 |
| Aktienkurs zum Tagesende | 2026/07/01 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Ironwood Pharmaceuticals, Inc. wird von 25 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Geoffrey Meacham | Barclays |
| Patrick Trucchio | Berenberg |
| David Maris | BMO Capital Markets Equity Research |